胆管癌的全身治疗
Systemic Therapy of Cholangiocarcinoma.
作者信息
Plentz Ruben R, Malek Nisar P
机构信息
Department of Internal Medicine I, Medical University Hospital, Tübingen, Germany.
出版信息
Visc Med. 2016 Dec;32(6):427-430. doi: 10.1159/000453084. Epub 2016 Nov 30.
Abstract
BACKGROUND
Cholangiocarcinoma (CC) is the second most common primary malignant liver disease. During the last decades, various novel therapies have been introduced in the field of oncology; nevertheless, the number of treatment options for CC is still limited.
METHODS
In this article, current palliative chemotherapy concepts as well as new drug therapies are outlined.
RESULTS
Gemcitabine and cisplatin are the standard treatment of care for patients with inoperable CC. Second-line chemotherapy is not standardized yet and is dependent on the first-line compounds. Antibodies against VEGFR and EGFR showed mixed or negative results. New molecular systemic treatments are not established yet.
CONCLUSION
Many clinical trials are still ongoing and new therapeutic strategies, including immunotherapies, are under active investigation.
摘要
背景
胆管癌（CC）是第二常见的原发性肝脏恶性疾病。在过去几十年中，肿瘤学领域引入了各种新型疗法；然而，CC的治疗选择仍然有限。
方法
本文概述了当前的姑息化疗概念以及新的药物疗法。
结果
吉西他滨和顺铂是无法手术切除的CC患者的标准治疗方案。二线化疗尚未标准化，且取决于一线用药。针对血管内皮生长因子受体（VEGFR）和表皮生长因子受体（EGFR）的抗体显示出混合或阴性结果。新的分子系统治疗方法尚未确立。
结论
许多临床试验仍在进行中，包括免疫疗法在内的新治疗策略正在积极研究中。
相似文献
1
Systemic Therapy of Cholangiocarcinoma.胆管癌的全身治疗
Visc Med. 2016 Dec;32(6):427-430. doi: 10.1159/000453084. Epub 2016 Nov 30.
2
Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.胆管癌的全身治疗：从化疗到靶向治疗。
Best Pract Res Clin Gastroenterol. 2015 Apr;29(2):345-53. doi: 10.1016/j.bpg.2015.01.002. Epub 2015 Feb 19.
3
The palliation of cholangiocarcinoma.胆管癌的姑息治疗。
Curr Opin Support Palliat Care. 2013 Jun;7(2):168-74. doi: 10.1097/SPC.0b013e32835f1e2f.
4
Medical therapy of advanced malignant epithelial tumours of the ovary.晚期卵巢恶性上皮性肿瘤的医学治疗
Forum (Genova). 2000 Oct-Dec;10(4):323-32.
5
The diagnosis and treatment of cholangiocarcinoma.胆管癌的诊断与治疗。
Dtsch Arztebl Int. 2014 Oct 31;111(44):748-54. doi: 10.3238/arztebl.2014.0748.
6
Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series.新辅助治疗后局部进展期肝内胆管细胞癌行肝移植治疗：一项前瞻性病例系列研究。
Lancet Gastroenterol Hepatol. 2018 May;3(5):337-348. doi: 10.1016/S2468-1253(18)30045-1. Epub 2018 Mar 13.
7
Patterns of failure following surgical resection for malignant pleural mesothelioma.恶性胸膜间皮瘤手术切除后的失败模式。
Thorac Surg Clin. 2004 Nov;14(4):567-73. doi: 10.1016/j.thorsurg.2004.06.006.
8
Advances in loco-regional palliation of unresectable cholangiocarcinomas.不可切除胆管癌的局部区域姑息治疗进展
Ann Palliat Med. 2014 Apr;3(2):65-74. doi: 10.3978/j.issn.2224-5820.2014.03.01.
9
[Medical management of cholangiocarcinomas in 2015].2015年胆管癌的医学管理
Bull Cancer. 2016 Apr;103(4):389-99. doi: 10.1016/j.bulcan.2016.01.019. Epub 2016 Feb 24.
10
Locoregional Therapies of Cholangiocarcinoma.胆管癌的局部区域治疗
Visc Med. 2016 Dec;32(6):414-420. doi: 10.1159/000453010. Epub 2016 Dec 5.
引用本文的文献
1
Durvalumab-Induced Immune Thrombocytopenia in Patients with Advanced Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization.度伐利尤单抗诱导的免疫性血小板减少症在接受钇-90放射性栓塞治疗的晚期胆管癌患者中的情况
Case Rep Oncol. 2024 Oct 18;17(1):1183-1193. doi: 10.1159/000541550. eCollection 2024 Jan-Dec.
2
High endothelial venule is a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma.高内皮静脉是肝内胆管癌切除术后具有预后意义的免疫相关生物标志物。
Cell Prolif. 2023 Dec;56(12):e13513. doi: 10.1111/cpr.13513. Epub 2023 Jul 3.
3
Optimal Management of Patients with Advanced or Metastatic Cholangiocarcinoma: An Evidence-Based Review.晚期或转移性胆管癌患者的最佳管理：一项基于证据的综述。
Cancer Manag Res. 2021 Oct 27;13:8085-8098. doi: 10.2147/CMAR.S276104. eCollection 2021.
4
[Influence of molecular pathology on oncological surgery of liver and bile duct tumors].[分子病理学对肝脏及胆管肿瘤肿瘤外科手术的影响]
Chirurg. 2021 Nov;92(11):1003-1010. doi: 10.1007/s00104-021-01495-6. Epub 2021 Sep 14.
5
Current challenges to underpinning the genetic basis for cholangiocarcinoma.当前支持胆管癌遗传基础的挑战。
Expert Rev Gastroenterol Hepatol. 2021 May;15(5):511-526. doi: 10.1080/17474124.2021.1915128. Epub 2021 Apr 23.
6
Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.肝内胆管癌：形态-分子病理学、肿瘤反应性微环境和恶性进展。
Adv Cancer Res. 2021;149:321-387. doi: 10.1016/bs.acr.2020.10.005. Epub 2020 Dec 9.
7
The Gastrointestinal Tumor Microenvironment: An Updated Biological and Clinical Perspective.胃肠道肿瘤微环境：最新的生物学与临床视角
J Oncol. 2019 Nov 22;2019:6240505. doi: 10.1155/2019/6240505. eCollection 2019.
8
MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment.MEK 抑制通过抑制细胞增殖和调节肿瘤微环境来抑制体外和体内的 K-Ras 野生型胆管癌。
Cell Death Dis. 2019 Feb 11;10(2):120. doi: 10.1038/s41419-019-1389-4.
9
[Intrahepatic cholangiocarcinoma - current perspectives and treatment algorithm].[肝内胆管癌——当前观点与治疗方案]
Chirurg. 2018 Nov;89(11):858-864. doi: 10.1007/s00104-018-0718-y.
10
Increased ETV4 expression correlates with estrogen-enhanced proliferation and invasiveness of cholangiocarcinoma cells.ETV4表达增加与雌激素增强胆管癌细胞的增殖和侵袭能力相关。
Cancer Cell Int. 2018 Feb 20;18:25. doi: 10.1186/s12935-018-0525-z. eCollection 2018.
本文引用的文献
1
Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial.吉西他滨与S-1联合化疗治疗不可切除肝门部胆管癌：一项随机开放标签临床试验
Oncotarget. 2016 May 3;7(18):26888-97. doi: 10.18632/oncotarget.8590.
2
Program Death 1 Immune Checkpoint and Tumor Microenvironment: Implications for Patients With Intrahepatic Cholangiocarcinoma.程序性死亡1免疫检查点与肿瘤微环境：对肝内胆管癌患者的意义
Ann Surg Oncol. 2016 Aug;23(8):2610-7. doi: 10.1245/s10434-016-5101-y. Epub 2016 Mar 24.
3
PD-L1 and HLA Class I Antigen Expression and Clinical Course of the Disease in Intrahepatic Cholangiocarcinoma.肝内胆管癌中PD-L1和HLA I类抗原表达与疾病临床进程
Clin Cancer Res. 2016 Jan 15;22(2):470-8. doi: 10.1158/1078-0432.CCR-15-0715. Epub 2015 Sep 15.
4
SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.SWOG S0809：一项关于肝外胆管癌和胆囊癌辅助性卡培他滨和吉西他滨治疗后放疗及同步卡培他滨的II期组间试验。
J Clin Oncol. 2015 Aug 20;33(24):2617-22. doi: 10.1200/JCO.2014.60.2219. Epub 2015 May 11.
5
A KRAS mutation status-stratified randomized phase II trial of gemcitabine and oxaliplatin alone or in combination with cetuximab in advanced biliary tract cancer.一项针对晚期胆道癌的 KRAS 突变状态分层随机 II 期试验，比较吉西他滨和奥沙利铂单药或联合西妥昔单抗的疗效。
Ann Oncol. 2015 May;26(5):943-949. doi: 10.1093/annonc/mdv035. Epub 2015 Jan 28.
6
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.一项在晚期胆道癌患者中进行的随机、多中心、II 期研究，比较了凡德他尼单药治疗与凡德他尼联合吉西他滨治疗与吉西他滨联合安慰剂治疗的疗效：VanGogh 研究。
Ann Oncol. 2015 Mar;26(3):542-7. doi: 10.1093/annonc/mdu576. Epub 2014 Dec 23.
7
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.吉西他滨联合索拉非尼对比吉西他滨单药治疗晚期胆道癌的双盲安慰剂对照多中心二期 AIO 研究：联合生物标志物和血清研究方案
Eur J Cancer. 2014 Dec;50(18):3125-35. doi: 10.1016/j.ejca.2014.09.013. Epub 2014 Oct 15.
8
Characterization of EGFR family gene aberrations in cholangiocarcinoma.胆管癌中表皮生长因子受体（EGFR）家族基因畸变的特征分析
Oncol Rep. 2014 Aug;32(2):700-8. doi: 10.3892/or.2014.3261. Epub 2014 Jun 13.
9
Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.吉西他滨和奥沙利铂联合或不联合西妥昔单抗治疗晚期胆道癌（BINGO）：一项随机、开放标签、非比较的 2 期临床试验。
Lancet Oncol. 2014 Jul;15(8):819-28. doi: 10.1016/S1470-2045(14)70212-8. Epub 2014 May 19.
10
Second-line chemotherapy in advanced biliary cancer: a systematic review.晚期胆道癌的二线化疗：系统评价。
Ann Oncol. 2014 Dec;25(12):2328-2338. doi: 10.1093/annonc/mdu162. Epub 2014 Apr 25.
Zotero 插件